Iridex Corporation logo

Iridex Corporation (IRIX)

Market Closed
10 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
1. 03
+0.03
+3%
$
15.61M Market Cap
- P/E Ratio
0% Div Yield
44,417 Volume
-0.37 Eps
$ 1
Previous Close
Day Range
1 1.03
Year Range
0.78 2.41
Want to track IRIX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 27 days
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral Cyclophotocoagulation) in managing both primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period.

Globenewswire | 6 months ago
Iridex Comments on Changing Glaucoma Reimbursement Landscape

Iridex Comments on Changing Glaucoma Reimbursement Landscape

MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today confirms that Local Coverage Determination (LCD) L37531, relating to Micro-Invasive Glaucoma Surgery (MIGS), was adopted as scheduled and will be effective for services performed on or after November 17, 2024. The Company has previously reported that it believes the reimbursement limitations created by the new LCD has potential to significantly increase physician interest in and use of Iridex's advanced laser-based treatments for glaucoma.

Globenewswire | 7 months ago
IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX ) Q3 2024 Earnings Call Transcript November 12, 2024 5:00 PM ET Company Participants Scott Shuda - Executive Chairman Patrick Mercer - CEO Fuad Ahmad - Interim CFO Operator Thank you all for participating in today's call. Joining me from the company are Scott Shuda, Executive Chairman; Patrick Mercer, Chief Executive Officer; and Fuad Ahmad, Interim Chief Financial Officer.

Seekingalpha | 7 months ago
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024.

Globenewswire | 8 months ago
Iridex Appoints Patrick Mercer as Chief Executive Officer

Iridex Appoints Patrick Mercer as Chief Executive Officer

MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. Mr. Shuda had previously served as Chairman.

Globenewswire | 9 months ago
Iridex Frustrates, But Expect A Transaction By Year-End

Iridex Frustrates, But Expect A Transaction By Year-End

IRIDEX has faced delays in selling its assets as part of a strategic review initiated a year ago, causing frustration among shareholders. Despite setbacks, the company remains committed to selling all assets and has taken steps to ensure financial sustainability during the process. The CEO expects agreements for the sale of assets by the end of 2024, potentially doubling the current share price within the next 3-6 months.

Seekingalpha | 10 months ago
IRIDEX Corporation (IRIX) Q2 2024 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q2 2024 Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Philip Taylor – Investor Relations David Bruce – Chief Executive Officer Fuad Ahmad – Interim Chief Financial Officer Conference Call Participants Tom Stephan – Stifel Operator Good day, and thank you for standing by. At this time I would like to welcome everyone to IRIDEX Second Quarter 2024 Earnings Conference Call.

Seekingalpha | 11 months ago
Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates

Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates

Iridex (IRIX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.17 per share a year ago.

Zacks | 11 months ago
IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript

IRIDEX Corporation (IRIX) Q1 2024 Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Trip Taylor - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to Q1 2024 IRIDEX Earnings Conference Call.

Seekingalpha | 1 year ago